Drugs public procurements on verge of serious crisis in Russia due to failed tenders
The segment of public procurement of medicines in Russia is facing a serious crisis due to the ever-growing number of failed tenders, caused by a low interest of suppliers and drugmakers for them, The Pharma Letter’s local correspondent reports.
According to data from the Russian Ministry of Health, in the first quarter 2024 the share of failed tenders in the overall structure of tenders for public procurements of drugs in the Russian pharmaceutical market grew from 15% to 32.9% year-on-year basis.
The government acknowledges the problem, explaining it by the lack of suppliers and suspension of production of certain drugs. Another reason is the ever-declining initial prices of auctions, which is caused by the ever growing number of generics in the local market and dumping policy that is used by certain suppliers and producers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze